TOI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Oncology Institute Inc (TOI) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 to invest. While the company shows promising growth potential with a 36.7% YoY revenue increase and analysts' positive outlook, the technical indicators are bearish, hedge funds are aggressively selling, and the stock's near-term trend suggests further downside. Given the lack of immediate positive catalysts or proprietary trading signals, it is prudent to hold off on buying until clearer signs of recovery or growth materialize.
The technical indicators for TOI are bearish. The MACD is negatively expanding below 0 (-0.03), the RSI is neutral at 23.121, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with resistance at 2.824 and support at 2.412. The stock trend analysis indicates a 60% chance of further decline in the short term (-0.8% in the next day, -1.23% in the next week, and -3.04% in the next month).
Analysts have initiated coverage with a Buy rating and a $5 price target, citing the company's potential to capitalize on value-based care adoption and durable 20%+ growth outlook. Revenue increased by 36.7% YoY in Q3 2025.
Hedge funds are aggressively selling, with a 47487.34% increase in selling activity over the last quarter. The company reported a net loss of $13.77M in Q3 2025, and EPS dropped by -22.22% YoY. Gross margin declined slightly to 12.59%. Technical indicators and stock trends suggest further downside in the near term.
In Q3 2025, TOI's revenue increased by 36.7% YoY to $136.56M, indicating strong top-line growth. However, the company remains unprofitable, with a net loss of $13.77M (up 4.14% YoY). EPS dropped by -22.22% YoY to -0.14, and gross margin declined slightly to 12.59%.
Needham initiated coverage with a Buy rating and a $5 price target, highlighting the company's potential to address rising oncology costs and achieve durable 20%+ growth. The shift toward value-based care is expected to improve EBITDA margins over the medium term.
